REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH

The Director General



الجمهورية اللبنان وزارة الصحة العامة المدير العام

رقم المحفوظات: 0 > 1 × × رقم اللصادر : ١٢/١/٢ • ١٢/١/٢ بيروت، في : ٢٦ تشيطول ٢٠١٣

جانب نقيب المستشفيات الخاصة في لبنان

الموضوع: إشعار بمتابعة جهاز طبي مغروس INFUSOR and INTERMATE Portable Elastomeric Infusion Systems

الجهاز المعنى بالمتابعة:

INFUSOR and INTERMATE Portable Elastomeric Infusion Systems
Trade Mark: Baxter Healthcare

- Local Representative:

نرجو الاطلاع على التوصية الصادرة عن وكالة

Medicine and Health Care Products Regulatory Agency (UK) MHRA

والتوصية الصادرة عن الشركة المصنعة والتي تشير الى خلل في عمل الصنف الوارد أعلاه، نرجو منكم تعميم هذه النشرة على جميع المستشفيات المعنية.

مرفق ربطا:

التوصية الصادرة عن الشركة المصنعة **غ:** دانرة البرامج والمشاريع المستشفيات الحكومية المحفوظات





PRODUCT SAFETY ALERT

September 2013

<u>Subject:</u> Field Safety Notice – Infusor / Folfusor / Intermate portable elastomeric infusion systems

Product codes: Please refer to the Attachment 1

Lot numbers: all

No. 461365

Dear Chief Pharmacist

Baxter Healthcare Ltd is providing you with important safety information regarding the Issue INFUSOR, FOLFUSOR, and INTERMATE portable elastomeric infusion systems. Description Please see Attachment 1 for listing of all applicable product codes. Baxter has received complaints for infusion flow rates greater than intended for the above referenced portable elastomeric infusion systems. In many cases, the complaint details an overinfusion of medication that are the result of uses inconsistent with the Instructions for Use. il a Delivery of medication at an infusion rate faster than intended may lead to toxicity Hazard Involved and changes to efficacy that require medical intervention. Baxter is requesting that healthcare providers continue to follow the device Action to be Instructions for Use which explains the following factors that may impact resulting taken by flow rate: healthcare providers 1. The choice of medication: Refer to the drug manufacturer's package insert for drug reconstitution/dilution and storage procedures. 2. Instructions for calculating the correct fill volumes including the potential for increase in flow rate which may result from a fill volume below the stated nominal fill volume. 3. Temperature change on the device. 4. Choice of the diluents (5% Dextrose vs. 0.9% Sodium Chloride) as a ~10% Baxter is a registered trademark of Baxter International, Inc. Baxter Healthcare Ltd Registered Office: Caxton Way / Thetford / Norfolk / IP24 3SE Registered in England

FCA-2013-078 Baxter, FOLFUSOR, INFUSOR, and INTERMATE are Trademarks of Baxter Healthcare, Inc Page 1 of 5

Baxter

increase in nominal flow rate may result when 0.9% Sodium Chloride is used.

- 5. The position of the Elastomeric Reservoir in relation to the Distal End Luer Lock. Flow rate will decrease ~0.5% for every inch the Elastomeric Reservoir is positioned below the distal end luer lock and increase ~0.5% for every inch the elastomeric reservoir is positioned above the distal end luer lock.
- 6. Length, diameter, and location of catheter

Baxter is requesting that you take the following actions in response to this notification:

Action to be taken in response to this notification

- 1. Acknowledge your receipt of this Safety Alert notification by completing the attached <u>Customer Reply Form</u> (Attachment 2) and return it to Baxter by using the contact details provided on the faxback form. Returning the Customer Reply Form promptly will prevent you from receiving repeat notifications.
- 2. If you distribute this product to other facilities or departments within your institution, please forward a copy of this communication to them to ensure that they are aware of this notice.
- 3. If you are a dealer, wholesaler, or distributor/reseller that distributed any product to other facilities, please notify your customers of this action.

Should you have any clinical questions related to this please contact Surecall Baxter Medical Information on 01635 206345 or email surecall@baxter.com.

Any adverse reactions or quality problems experienced with the use of these products may be reported using one of the following options:

Reporting product quality complaints:

- Calling 01604 704 603
- Faxing to: 01604 704688
- Emailing to: uk shs qad@baxter.com

Reporting adverse events with drugs:

- Calling 01635 206 360,
- Faxing to: 01635 206 281,
- · Emailing to: vigilanceuk@baxter.com

The MHRA has been notified of this action.

Sincerely,

lonner

Joanna Lorimer Product Manager Medical Products Baxter Healthcare Ltd, Wallingford Road Compton, Newbury, Berkshire RG20 7QW

 Attachment 1:
 INFUSOR / FOLFUSOR / INTERMATE Product Code Listing

 Attachment 2:
 Customer Reply Form

 FCA-2013-078
 Baxter, FOLFUSOR, INFUSOR, and INTERMATE are Trademarks of Baxter Healthcare, Inc

Page 2 of 5



Attachment 1 Safety Alert – INFUSOR / FOLFUSOR / INTERMATE Product Code Listing

PRODUCT CODE	DESCRIPTION	
NFUSOR – Portable	Elastomeric Infusion System	
2С1071КЈР	Singleday INFUSOR	
2С1073КЈР	Half Day INFUSOR	
2C1075KJP	Two Day INFUSOR	
2C1080KJP	Multiday INFUSOR	
2C1082KJP	Seven Day INFUSOR	
S2C1083KJP	Desferrioxamine INFUSOR	
INFUSOR LV - Portabl	e Elastomeric Infusion System	
2С1087КР	INFUSOR LV 1.5	
2C1008KP	INFUSOR LV 2	
2C1009ÅP	INFUSOR LV 5	
2С1156КР	INFUSOR LV 7	
2С1063КР	INFUSOR LV 10	
INFUSOR SV - Portab	le Elastomeric Infusion System	
2С1700КР	INFUSOR SV 0.5	
2C1701KP	INFUSOR SV 1	
2С1702КР	INFUSOR SV 2	
INFUSOR XLV - Portal	ble Elastomeric Infusion System	
2C1168K	INFUSOR XLV 8	
FOLFusor - Portable	Elstomeric Infusion System	

FCA-2013-078

Baxter is a registered trademark of Baxter International, Inc.

Attachment 1 Page 3 of 5



2C4701K	FOLFusor SV 1	
2C4711K	FOLFusor SV 2.5	
2С4009К	FOLFusor LV 5	
2C4063K	FOLFusor LV 10	
Basal/Bolus INFUSOR	- Portable Elastomeric Infusion System	
2C1976KJ	Basal/Bolus INFUSOR 2 ml/h x 2 ml/h System	
MULTIRATE INFUSOR	- Portable Elastomeric Infusion System	
2C1154KP	MULTIRATE INFUSOR SV 1.0-2.0-3.0	
2C1155KP	MULTIRATE INFUSOR LV 2.0-3.0-5.0	
2C9960KP	MULTIRATE INFUSOR LV 5-7-12	
2C9961KP	MULTIRATE INFUSOR LV 2.0-4.0-6.0	
Regional Analgesia INI	FUSOR System with Patient Control Module	
2C1811K	Regional Analgesia INFUSOR System with Patient Control Module 5.0- 7.0-12.0	
A state of the second second	Elastomeric Infusion System	
2C1710K	INTERMATE SV 50 -Single-pack	
2C1730K	INTERMATE SV 50 -Multi-pack	
2С1712К	INTERMATE SV 100 - Single-pack	
2C1732K	INTERMATE SV 100 - Multi-pack	
2С1714К .	INTERMATE SV 200 - Single-pack	
2С1734К	INTERMATE SV 200 - Multi-pack	
2С1720К	INTERMATE LV 50 - Single-pack	
2C1742K	INTERMATE LV 100 - Multi-pack	
2C1724K	INTERMATE LV 250	
2C1744K	INTERMATE LV 250	
2C1754K	INTERMATE XLV 250	

FCA-2013-078

Baxter is a registered trademark of Baxter International, Inc.

Attachment 1 Page 4 of 5